Should I buy or sell Organogenesis stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ORGO shares. View ORGO analyst ratings or view top-rated stocks .

What is Organogenesis' stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Organogenesis' stock. Their ORGO share price targets range from $3.50 to $6.00. On average, they anticipate the company's stock price to reach $4.83 in the next year. This suggests a possible upside of 69.0% from the stock's current price. View analysts price targets for ORGO or view top-rated stocks among Wall Street analysts .

How have ORGO shares performed in 2024?

Organogenesis' stock was trading at $4.09 on January 1st, 2024. Since then, ORGO shares have decreased by 30.1% and is now trading at $2.86. View the best growth stocks for 2024 here .

When is Organogenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ORGO earnings forecast .

How can I listen to Organogenesis' earnings call?

Organogenesis will be holding an earnings conference call on Thursday, May 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc. (NASDAQ:ORGO) released its quarterly earnings data on Tuesday, November, 9th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. The business earned $113.75 million during the quarter, compared to analysts' expectations of $112.10 million. Organogenesis had a trailing twelve-month return on equity of 1.81% and a net margin of 1.14%. During the same quarter in the prior year, the business posted $0.19 earnings per share.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $445.0 million-$470.0 million, compared to the consensus revenue estimate of $456.0 million.

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Strongbridge Biopharma (SBBP) , vTv Therapeutics (VTVT) , Cerecor (CERC) , Marker Therapeutics (MRKR) , Matinas BioPharma (MTNB) , OPKO Health (OPK) , Ovid Therapeutics (OVID) , Sorrento Therapeutics (SRNE) , DURECT (DRRX) and Evofem Biosciences (EVFM) .

Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.38%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani , Antonio S Montecalvo, Arthur S Leibowitz, Dennis Erani , Gary S Gillheeney, Gary S Gillheeney , Glenn H Nussdorf , Michael W Katz and Michael W Katz . View institutional ownership trends .

How do I buy shares of Organogenesis?

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ORGO

Organogenesis (ORGO) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ORGO Stock Alerts

$2.86

+0.07 (+2.51%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.77
▼
$2.88
50-Day Range: $2.61
▼
$3.84
52-Week Range: $1.79
▼
$4.70

Volume: 787,668 shs
Average Volume: 762,737 shs
Market Capitalization: $377.41 million

P/E Ratio: 71.52
Dividend Yield: N/A
Price Target: $4.83

Get Organogenesis alerts:

Organogenesis MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 69.0% Upside
$4.83 Price Target
Short Interest: Healthy
9.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.01
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

188th out of 918 stocks

Pharmaceutical Preparations Industry

71st out of 402 stocks

3.3

Analyst's Opinion

Consensus Rating
Organogenesis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Organogenesis has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
9.35% of the float of Organogenesis has been sold short.
Short Interest Ratio / Days to Cover
Organogenesis has a short interest ratio ("days to cover") of 9.4.
Change versus previous month
Short interest in Organogenesis has recently decreased by 9.74%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Organogenesis does not currently pay a dividend.
Dividend Growth
Organogenesis does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Organogenesis has received a 64.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Wound dressings" and "Allografts" products. See details.
Environmental Sustainability
The Environmental Impact score for Organogenesis is -1.01.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Organogenesis this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for ORGO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Organogenesis to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Organogenesis insiders have not sold or bought any company stock.
Percentage Held by Insiders
34.00% of the stock of Organogenesis is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
49.57% of the stock of Organogenesis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Organogenesis is 71.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.71.
Price to Earnings Ratio vs. Sector
The P/E ratio of Organogenesis is 71.52, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 255.77.
Price to Book Value per Share Ratio
Organogenesis has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Organogenesis Stock (NASDAQ:ORGO)

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

ORGO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ORGO Stock News Headlines

April 16, 2024 | globenewswire.com

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

April 3, 2024 | globenewswire.com

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 19, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Organogenesis Holdings Amid Stable Product Pricing and Positive Market Dynamics

March 7, 2024 | barrons.com

Organogenesis Holdings Inc. Cl A

March 2, 2024 | finance.yahoo.com

Organogenesis Holdings Inc. (NASDAQ:ORGO) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Organogenesis Holdings Full Year 2023 Earnings: Misses Expectations

March 1, 2024 | fool.com

Why Organogenesis Holding Stock Plummeted by 18% Today

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 1, 2024 | msn.com

Organogenesis (ORGO) Q4 2023 Earnings Call Transcript

February 29, 2024 | benzinga.com

Recap: Organogenesis Hldgs Q4 Earnings

February 29, 2024 | finance.yahoo.com

Organogenesis Holdings Inc (ORGO) Faces Revenue Decline in Q4 and FY 2023, Aims for Growth in 2024

February 29, 2024 | globenewswire.com

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

February 28, 2024 | benzinga.com

A Preview Of Organogenesis Hldgs's Earnings

February 15, 2024 | money.usnews.com

Organogenesis Holdings Inc - Ordinary Shares - Class A

February 12, 2024 | finance.yahoo.com

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

February 8, 2024 | msn.com

Cantor starts Organogenesis at overweight, cites differentiated portfolio

February 8, 2024 | finance.yahoo.com

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

January 15, 2024 | finance.yahoo.com

Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice

January 14, 2024 | finance.yahoo.com

Shareholders in Organogenesis Holdings (NASDAQ:ORGO) are in the red if they invested five years ago

December 30, 2023 | benzinga.com

Organogenesis Hldgs Stock (NASDAQ:ORGO), Guidance and Forecast

December 28, 2023 | finance.yahoo.com

Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?

December 18, 2023 | finance.yahoo.com

Organogenesis Holdings Inc. (NASDAQ:ORGO) Surges 42% Yet Its Low P/S Is No Reason For Excitement

December 7, 2023 | finance.yahoo.com

Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Stock Is Going Strong: Have Financials A Role To Play?

November 30, 2023 | msn.com

Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)

November 27, 2023 | msn.com

Organogenesis Holdings Inc - (ORGO) Price Target Increased by 7.14% to 3.83

November 24, 2023 | stocknews.com

3 Biotech Stocks Flowing With Investment Potential

See More Headlines

Receive ORGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organogenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/18/2024
Next Earnings (Confirmed): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ORGO
CUSIP: N/A
CIK: 1661181
Web: organogenesis.com
Phone: (781) 575-0775
Fax: N/A
Employees: 862
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.83
High Stock Price Target: $6.00
Low Stock Price Target: $3.50
Potential Upside/Downside: +69.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.04
Trailing P/E Ratio: 71.52
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $4.95 million
Net Margins: 1.14%
Pretax Margin: 2.40%
Return on Equity: 1.81%
Return on Assets: 1.09%

Debt

Debt-to-Equity Ratio: 0.22
Current Ratio: 2.80
Quick Ratio: 2.44

Sales & Book Value

Annual Sales: $433.14 million
Price / Sales: 0.87
Cash Flow: $0.22 per share
Price / Cash Flow: 13.30
Book Value: $2.11 per share
Price / Book: 1.36

Miscellaneous

Outstanding Shares: 131,960,000
Free Float: 87,096,000
Market Cap: $377.41 million
Optionable: Optionable
Beta: 1.57

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Gary S. Gillheeney Sr. (Age 69)
President, CEO, Chair of the Board
Comp: $1.06M
Mr. David C. Francisco (Age 58)
Chief Financial Officer
Comp: $473.14k
Mr. Patrick Bilbo (Age 62)
Chief Operating Officer
Comp: $537.07k
Ms. Lori H. Freedman B.A. (Age 57)
Esq., J.D., Chief Administrative & Legal Officer
Comp: $489.41k
Mr. Brian Grow (Age 47)
Chief Commercial Officer
Comp: $513.06k
Mr. William R. Kolb CPA
Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ORGO Stock Analysis - Frequently Asked Questions

Should I buy or sell Organogenesis stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ORGO shares.
View ORGO analyst ratings or view top-rated stocks.
What is Organogenesis' stock price target for 2024?: 3 equities research analysts have issued 12-month price objectives for Organogenesis' stock. Their ORGO share price targets range from $3.50 to $6.00. On average, they anticipate the company's stock price to reach $4.83 in the next year. This suggests a possible upside of 69.0% from the stock's current price.
View analysts price targets for ORGO or view top-rated stocks among Wall Street analysts.
How have ORGO shares performed in 2024?: Organogenesis' stock was trading at $4.09 on January 1st, 2024. Since then, ORGO shares have decreased by 30.1% and is now trading at $2.86.
View the best growth stocks for 2024 here.
When is Organogenesis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ORGO earnings forecast.
How can I listen to Organogenesis' earnings call?: Organogenesis will be holding an earnings conference call on Thursday, May 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Organogenesis' earnings last quarter?: Organogenesis Holdings Inc. (NASDAQ:ORGO) released its quarterly earnings data on Tuesday, November, 9th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. The business earned $113.75 million during the quarter, compared to analysts' expectations of $112.10 million. Organogenesis had a trailing twelve-month return on equity of 1.81% and a net margin of 1.14%. During the same quarter in the prior year, the business posted $0.19 earnings per share.

What guidance has Organogenesis issued on next quarter's earnings?: Organogenesis issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $445.0 million-$470.0 million, compared to the consensus revenue estimate of $456.0 million.
What other stocks do shareholders of Organogenesis own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Strongbridge Biopharma (SBBP), vTv Therapeutics (VTVT), Cerecor (CERC), Marker Therapeutics (MRKR), Matinas BioPharma (MTNB), OPKO Health (OPK), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), DURECT (DRRX) and Evofem Biosciences (EVFM).
Who are Organogenesis' major shareholders?: Organogenesis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.38%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Antonio S Montecalvo, Arthur S Leibowitz, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Michael W Katz and Michael W Katz.
View institutional ownership trends.
How do I buy shares of Organogenesis?: Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ORGO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Organogenesis (ORGO) Stock Price, News & Analysis

Organogenesis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Organogenesis Stock (NASDAQ:ORGO)

ORGO Stock Price History

ORGO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ORGO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™